WHO classification of chronic myeloid leukemia/myeloproliferative neoplasia.
| Chronic phase |
|
| Accelerated phase |
- 15-19% blasts in blood or bone marrow or
- ≥ 20 % basophilia in the blood (increase in basophilic granulocytes/subgroup of leukocytes (white blood cells)) – indication that the severity of the disease is increasing, or
- Persistent (continuing), therapy-independent thrombocytopenia (pathological reduction in platelets/platelets: < 100 x 109/L) or
- Development of additional chromosomal aberrations (abnormalities) in Ph+ cells (Philadelphia chromosome) despite treatment or
- Thrombocytosis (abnormal proliferation of platelets (blood platelets); > 1,999 x 109/L) that does not respond to therapy or
- Progressive splenomegaly (progressive splenomegaly) and rising leukocytes that do not respond to therapy
|
| Blast crisis |
- ≥ 20% blasts in blood or bone marrow or
- Evidence of extramedullary blasts (outside the spleen) or
- Large blast foci or clusters detectable in bone marrow biopsy.
|
European LeukemiaNet classification (ELN classification) of chronic myeloid leukemia/myeloproliferative neoplasia.
| Chronic phase |
|
| Accelerated phase |
- 15-29% blasts in blood or bone marrow or
- ≥ 30 % blasts + promyelocytes (precursor form of granulocytes/subgroup of leukocytes (white blood cells)) in blood or bone marrow (blasts < 30 %) or
- ≥ 20 % basophilia in the blood (proliferation of basophilic granulocytes) or
- Persistent (persisting), therapy-independent thrombocytopenia (pathological reduction of platelets/platelets; < 100 x 109/L) or
- Development of additional chromosomal aberrations (abnormalities) in Ph+ cells (Philadelphia chromosome) despite treatment.
|
| Blast crisis |
- ≥ 30% blasts in blood or bone marrow or
- Evidence of extramedullary blasts (outside the spleen).
|
